Australian biotech market watch 30/09/09
Wednesday, 30 September, 2009
A rather flat day on the markets on this last day of September, with the All Ordinaries sitting around the 4,746 mark as of 2:00pm this afternoon and the heath care indices following suit.
Of the Big Three, bionic ear pioneer, Cochlear (ASX:COH) is up a modest 63c to $67.39 and ResMed (ASX:RMD) remains flat at $5.17. CSL (ASX:CSL), which has been in the news of late with controversy over the national rollout of H1N1 vaccines, is down 36c, or 1.1% to $33.39.
Ansell (ASX:ANN) managed to lift by 1.62% to $10.06 in low volume trading after a rather flat couple of weeks.
The only other movers are Fisher & Paykel Healthcare, up 1.9% to $2.69, recovering some of the losses it's experienced since its high of $2.80 at the beginning of September, and Sonic Healthcare, up 38c to $14.24, which is 3.8% for the week.
Eye disease specialist, pSivida (ASX:PVA), dropped 57c to $4.95 after it announced early safety and efficacy results of its drug Iluvien, which proved "promising".
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
